S&P Futures
4,454.25 -20.50 (-0.46%) Dow Futures
34,530.00 -86.00 (-0.25%) Nasdaq Futures
14,728.75 -112.25 (-0.76%) Russell 2000 Futures
2,015.90 -5.30 (-0.26%) Crude Oil
84.86 -0.69 (-0.81%) Gold
1,840.70 -1.90 (-0.10%)
Fate Therapeutics, Inc. (FATE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 39.31 |
| Open | 40.20 |
| Bid | 35.50 x 900 |
| Ask | 40.68 x 1200 |
| Day's Range | 37.97 - 41.95 |
| 52 Week Range | 37.97 - 118.14 |
| Volume | |
| Avg. Volume | 1,199,575 |
| Market Cap | 3.657B |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.12 |
| Earnings Date | Feb 22, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 99.44 |
Fair Value
Related Research
- Fate Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 01/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat7 days agoArgus Research
- GlobeNewswire
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Antigen Binding Domain of FT536 has been Shown to Overcome MICA/B Shedding, a Common Mechanism of Tumor Cell Escape Broadly Observed Across Solid Tumors Six-arm Phase 1 Clinical Study to Evaluate Multi-dose, Multi-cycle Treatment Schedule of FT536 as Monotherapy and
- GuruFocus.com
MainStay VP Small Cap Growth Portfolio Buys Option Care Health Inc, Leslies Inc, Kratos Defense ...
Investment company MainStay VP Small Cap Growth Portfolio (Current Portfolio) buys Option Care Health Inc, Leslies Inc, Kratos Defense & Security Solutions Inc, 908 Devices Inc, SelectQuote Inc, sells Globant SA, Asana Inc, The Hain Celestial Group Inc, SiTime Corp, Vroom Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, MainStay VP Small Cap Growth Portfolio.
- GuruFocus.com
Fate Therapeutics Inc (FATE) CFO Edward J Dulac Iii Sold $958,620 of Shares
CFO of Fate Therapeutics Inc (30-Year Financial, Insider Trades) Edward J Dulac Iii (insider trades) sold 15,977 shares of FATE on 12/20/2021 at an average price of $60 a share.
